SG11201808354PA - Column-based fully scalable raav manufacturing process - Google Patents
Column-based fully scalable raav manufacturing processInfo
- Publication number
- SG11201808354PA SG11201808354PA SG11201808354PA SG11201808354PA SG11201808354PA SG 11201808354P A SG11201808354P A SG 11201808354PA SG 11201808354P A SG11201808354P A SG 11201808354PA SG 11201808354P A SG11201808354P A SG 11201808354PA SG 11201808354P A SG11201808354P A SG 11201808354PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- aiex
- avb
- pennsylvania
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size selective separation, e.g. size exclusion chromatography, gel filtration, permeation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/16—Diafiltration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316252P | 2016-03-31 | 2016-03-31 | |
| PCT/US2017/025396 WO2017173283A1 (en) | 2016-03-31 | 2017-03-31 | Column-based fully scalable raav manufacturing process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808354PA true SG11201808354PA (en) | 2018-10-30 |
Family
ID=59966426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808354PA SG11201808354PA (en) | 2016-03-31 | 2017-03-31 | Column-based fully scalable raav manufacturing process |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11702639B2 (ja) |
| EP (1) | EP3436051B1 (ja) |
| JP (2) | JP7364306B2 (ja) |
| KR (1) | KR102405250B1 (ja) |
| CN (1) | CN109152821A (ja) |
| AU (1) | AU2017240721B2 (ja) |
| BR (1) | BR112018070256A2 (ja) |
| CA (1) | CA3019133A1 (ja) |
| CL (1) | CL2018002754A1 (ja) |
| CO (1) | CO2018011151A2 (ja) |
| DK (1) | DK3436051T3 (ja) |
| ES (1) | ES2896080T3 (ja) |
| HU (1) | HUE056854T2 (ja) |
| IL (1) | IL261970A (ja) |
| LT (1) | LT3436051T (ja) |
| MY (1) | MY195391A (ja) |
| PE (1) | PE20190434A1 (ja) |
| PH (1) | PH12018502104A1 (ja) |
| PL (1) | PL3436051T3 (ja) |
| PT (1) | PT3436051T (ja) |
| RU (1) | RU2754467C2 (ja) |
| SA (1) | SA518400146B1 (ja) |
| SG (1) | SG11201808354PA (ja) |
| WO (1) | WO2017173283A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017005834A (es) | 2014-11-05 | 2017-11-17 | Voyager Therapeutics Inc | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. |
| RU2749882C2 (ru) | 2014-11-14 | 2021-06-18 | Вояджер Терапьютикс, Инк. | Модулирующие полинуклеотиды |
| EP3218484A4 (en) | 2014-11-14 | 2018-05-30 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| BR112018070256A2 (pt) * | 2016-03-31 | 2019-01-29 | Spark Therapeutics Inc | processo de fabricação de raav totalmente escalável à base de colunas |
| RU2758488C2 (ru) | 2016-05-18 | 2021-10-28 | Вояджер Терапьютикс, Инк. | Модулирующие полинуклеотиды |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| KR102669561B1 (ko) * | 2017-06-30 | 2024-05-24 | 스파크 테라퓨틱스, 인코포레이티드 | Aav 벡터 컬럼 정제 방법 |
| IL314692A (en) * | 2017-11-08 | 2024-10-01 | Novartis Ag | Means and method for preparing viral vectors and their uses |
| WO2019209632A1 (en) | 2018-04-24 | 2019-10-31 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
| JPWO2022045055A1 (ja) * | 2020-08-24 | 2022-03-03 | ||
| WO2023077085A2 (en) * | 2021-10-29 | 2023-05-04 | Oxford Biomedica Solutions Llc | Methods and compositions for the purification of adeno-associated virus |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| WO1992001070A1 (en) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| US5981716A (en) * | 1995-06-07 | 1999-11-09 | Gruppo Lepettit, S.P.A. | Process for the purification of proteins |
| US6001650A (en) | 1995-08-03 | 1999-12-14 | Avigen, Inc. | High-efficiency wild-type-free AAV helper functions |
| US6004797A (en) | 1995-11-09 | 1999-12-21 | Avigen, Inc. | Adenovirus helper-free recombinant AAV Virion production |
| DK1944362T3 (en) * | 1997-09-05 | 2016-01-25 | Genzyme Corp | Fremgangsmåder til fremstilling af hjælpevirusfri præparater med høj titer af rekombinante AAV-vektorer |
| US7125705B2 (en) | 2000-04-28 | 2006-10-24 | Genzyme Corporation | Polynucleotides for use in recombinant adeno-associated virus virion production |
| US6593123B1 (en) | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| US7419817B2 (en) | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
| ATE490307T1 (de) * | 2003-05-21 | 2010-12-15 | Genzyme Corp | Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind |
| ES2714007T3 (es) | 2007-04-09 | 2019-05-24 | Univ Florida | Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso |
| SG176283A1 (en) * | 2009-06-16 | 2012-01-30 | Genzyme Corp | Improved methods for purification of recombinant aav vectors |
| EP2325194A1 (en) * | 2009-11-24 | 2011-05-25 | Glycotope GmbH | Process for the purification of glycoproteins |
| AU2011209743B2 (en) | 2010-01-28 | 2016-03-10 | The Children's Hospital Of Philadelphia | A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy |
| JP2014528729A (ja) | 2011-10-05 | 2014-10-30 | モルメド エスピーエー | ウイルスベクター精製システム |
| BR112018070256A2 (pt) * | 2016-03-31 | 2019-01-29 | Spark Therapeutics Inc | processo de fabricação de raav totalmente escalável à base de colunas |
-
2017
- 2017-03-31 BR BR112018070256A patent/BR112018070256A2/pt unknown
- 2017-03-31 ES ES17776783T patent/ES2896080T3/es active Active
- 2017-03-31 SG SG11201808354PA patent/SG11201808354PA/en unknown
- 2017-03-31 DK DK17776783.7T patent/DK3436051T3/da active
- 2017-03-31 LT LTEPPCT/US2017/025396T patent/LT3436051T/lt unknown
- 2017-03-31 CA CA3019133A patent/CA3019133A1/en active Pending
- 2017-03-31 PL PL17776783T patent/PL3436051T3/pl unknown
- 2017-03-31 PT PT177767837T patent/PT3436051T/pt unknown
- 2017-03-31 MY MYPI2018001663A patent/MY195391A/en unknown
- 2017-03-31 US US16/088,743 patent/US11702639B2/en active Active
- 2017-03-31 HU HUE17776783A patent/HUE056854T2/hu unknown
- 2017-03-31 AU AU2017240721A patent/AU2017240721B2/en active Active
- 2017-03-31 JP JP2018550782A patent/JP7364306B2/ja active Active
- 2017-03-31 KR KR1020187031464A patent/KR102405250B1/ko active IP Right Grant
- 2017-03-31 CN CN201780022146.8A patent/CN109152821A/zh active Pending
- 2017-03-31 EP EP17776783.7A patent/EP3436051B1/en active Active
- 2017-03-31 WO PCT/US2017/025396 patent/WO2017173283A1/en active Application Filing
- 2017-03-31 PE PE2018001938A patent/PE20190434A1/es unknown
- 2017-03-31 RU RU2018138164A patent/RU2754467C2/ru active
-
2018
- 2018-09-26 IL IL261970A patent/IL261970A/en unknown
- 2018-09-27 CL CL2018002754A patent/CL2018002754A1/es unknown
- 2018-09-28 PH PH12018502104A patent/PH12018502104A1/en unknown
- 2018-09-30 SA SA518400146A patent/SA518400146B1/ar unknown
- 2018-10-18 CO CONC2018/0011151A patent/CO2018011151A2/es unknown
-
2022
- 2022-06-07 JP JP2022092235A patent/JP2022120011A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2018002754A1 (es) | 2019-02-01 |
| PL3436051T3 (pl) | 2022-02-07 |
| EP3436051B1 (en) | 2021-07-28 |
| SA518400146B1 (ar) | 2021-10-19 |
| IL261970A (en) | 2018-10-31 |
| RU2018138164A3 (ja) | 2020-06-16 |
| US11702639B2 (en) | 2023-07-18 |
| JP2022120011A (ja) | 2022-08-17 |
| BR112018070256A2 (pt) | 2019-01-29 |
| JP2019509745A (ja) | 2019-04-11 |
| RU2018138164A (ru) | 2020-04-30 |
| JP7364306B2 (ja) | 2023-10-18 |
| KR20190006951A (ko) | 2019-01-21 |
| DK3436051T3 (da) | 2021-11-01 |
| HUE056854T2 (hu) | 2022-03-28 |
| CA3019133A1 (en) | 2017-10-05 |
| AU2017240721A1 (en) | 2018-10-11 |
| CN109152821A (zh) | 2019-01-04 |
| AU2017240721B2 (en) | 2023-10-12 |
| PE20190434A1 (es) | 2019-03-21 |
| WO2017173283A1 (en) | 2017-10-05 |
| KR102405250B1 (ko) | 2022-06-02 |
| US20200299650A1 (en) | 2020-09-24 |
| PT3436051T (pt) | 2021-11-02 |
| LT3436051T (lt) | 2021-11-25 |
| ES2896080T3 (es) | 2022-02-23 |
| CO2018011151A2 (es) | 2019-04-30 |
| EP3436051A1 (en) | 2019-02-06 |
| RU2754467C2 (ru) | 2021-09-02 |
| MY195391A (en) | 2023-01-18 |
| EP3436051A4 (en) | 2019-10-16 |
| PH12018502104A1 (en) | 2019-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808354PA (en) | Column-based fully scalable raav manufacturing process | |
| SG11201808220VA (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201804400SA (en) | Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use | |
| SG11201900366QA (en) | Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby | |
| SG11201808215SA (en) | Aluminum alloys having iron, silicon, vanadium and copper, and with a high volume of ceramic phase therein | |
| SG11201810834WA (en) | Hepatitis b antiviral agents | |
| SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201408791TA (en) | Dihydropyrimidine compounds and their application in pharmaceuticals | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| SG11201407402TA (en) | Carbazole-containing sulfonamides as cryptochrome modulators | |
| SG11201804770QA (en) | Method and arrangement for recovery of salt | |
| SG11201811161YA (en) | Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201407800SA (en) | Selective binding of biological targets to solid phase ureides | |
| SG11201805170XA (en) | Cellular glycosaminoglycan compositions and methods of making and using | |
| SG11201807885PA (en) | Compositions and methods for making antibodies based on use of expression-enhancing loci | |
| SG11201809793UA (en) | Tl1a antibodies and uses thereof | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases |